- Home
- MSM vs AKRO Comparison
MSM vs AKRO Comparison
Compare MSM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSM
- AKRO
- Stock Information
- Founded
- MSM 1941
- AKRO 2017
- Country
- MSM United States
- AKRO United States
- Employees
- MSM N/A
- AKRO N/A
- Industry
- MSM Industrial Machinery/Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MSM Industrials
- AKRO Health Care
- Exchange
- MSM Nasdaq
- AKRO Nasdaq
- Market Cap
- MSM 4.6B
- AKRO 3.9B
- IPO Year
- MSM 1995
- AKRO 2019
- Fundamental
- Price
- MSM $81.12
- AKRO $54.28
- Analyst Decision
- MSM Hold
- AKRO Strong Buy
- Analyst Count
- MSM 6
- AKRO 8
- Target Price
- MSM $85.40
- AKRO $82.50
- AVG Volume (30 Days)
- MSM 412.2K
- AKRO 2.0M
- Earning Date
- MSM 07-01-2025
- AKRO 05-12-2025
- Dividend Yield
- MSM 4.19%
- AKRO N/A
- EPS Growth
- MSM N/A
- AKRO N/A
- EPS
- MSM 3.80
- AKRO N/A
- Revenue
- MSM $3,751,835,000.00
- AKRO N/A
- Revenue This Year
- MSM N/A
- AKRO N/A
- Revenue Next Year
- MSM $3.66
- AKRO N/A
- P/E Ratio
- MSM $21.35
- AKRO N/A
- Revenue Growth
- MSM N/A
- AKRO N/A
- 52 Week Low
- MSM $68.10
- AKRO $20.34
- 52 Week High
- MSM $90.81
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MSM 54.96
- AKRO 70.44
- Support Level
- MSM $79.66
- AKRO $44.94
- Resistance Level
- MSM $81.73
- AKRO $51.66
- Average True Range (ATR)
- MSM 1.71
- AKRO 3.17
- MACD
- MSM -0.10
- AKRO 0.90
- Stochastic Oscillator
- MSM 51.62
- AKRO 91.31
About MSM MSC Industrial Direct Company Inc.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations (MRO) supplies. MSC primarily operates within North America where it derives over 95% of its revenue.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.